Currently submitted to: JMIR mHealth and uHealth
Date Submitted: Jan 16, 2020
Open Peer Review Period: Jan 16, 2020 - Feb 20, 2020
(closed for review but you can still tweet)
NOTE: This is an unreviewed Preprint
Warning: This is a unreviewed preprint (What is a preprint?). Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn (a note “no longer under consideration” will appear above).
Peer-review me: Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period (in this case, a “Peer-Review Me” button to sign up as reviewer is displayed above). All preprints currently open for review are listed here. Outside of the formal open peer-review period we encourage you to tweet about the preprint.
Citation: Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author).
Final version: If our system detects a final peer-reviewed “version of record” (VoR) published in any journal, a link to that VoR will appear below. Readers are then encourage to cite the VoR instead of this preprint.
Settings: If you are the author, you can login and change the preprint display settings, but the preprint URL/DOI is supposed to be stable and citable, so it should not be removed once posted.
Submit: To post your own preprint, simply submit to any JMIR journal, and choose the appropriate settings to expose your submitted version as preprint.
Telemonitoring for elderly patients with hospital discharge for heart failure: A cost-effectiveness analysis
Telemonitoring (TM)-guided interventional management reduces hospitalization and mortality of patients with chronic heart failure (CHF).
To analyze the cost-effectiveness of usual care (UC) with and without TM-guided management in patients discharged for CHF from the perspective of US healthcare providers.
A life-long Markov model was designed to estimate outcomes of (1) UC alone for all post-discharged CHF patients (New York Heart Association (NYHA) class I-IV), (2) UC plus TM for all post-discharged CHF patients, (3) UC for all post-discharged CHF patients plus TM for patients with NYHA class III-IV; (4) UC for all post-discharged CHF patients plus TM for patients with NYHA class II-IV. Model inputs were derived from literature and public data. Sensitivity analyses were conducted to assess robustness of model results. Primary outcomes were total direct medical cost, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratio (ICER).
In base-case analysis, universal TM group gained highest QALYs (6.2967 QALYs), followed by TM for NYHA class II-IV group (6.2960 QALYs), TM for NYHA class III-IV group (6.2450 QALYs), and UC alone (6.1530 QALYs). ICERs of TM for NYHA class III-IV (35,393 USD/QALY) and TM for NYHA class II-IV groups (38,261 USD/QALY) were lower than the ICER of universal TM group (100,458 USD/QALY). In probabilistic sensitivity analysis, probabilities of universal TM, TM for NYHA class II-IV, TM for NYHA class III-IV, and universal UC to be accepted as cost-effective at USD50,000/QALY were 2.76%, 76.31%, 18.6%, and 2.33%, respectively.
UC for all discharged CHF patients plus TM-guided management for NYHA class II-IV patients appears to be the preferred cost-effective strategy.
Request queued. Please wait while the file is being generated. It may take some time.
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.